JP6246227B2 - Tarp−ガンマ8依存性ampa受容体アンタゴニストとしての6−((s)−1−{1−[5−(2−ヒドロキシ−エトキシ)−ピリジン−2−イル]−1h−ピラゾール−3−イル}−エチル)−3h−1,3−ベンゾチアゾール−2−オン - Google Patents

Tarp−ガンマ8依存性ampa受容体アンタゴニストとしての6−((s)−1−{1−[5−(2−ヒドロキシ−エトキシ)−ピリジン−2−イル]−1h−ピラゾール−3−イル}−エチル)−3h−1,3−ベンゾチアゾール−2−オン Download PDF

Info

Publication number
JP6246227B2
JP6246227B2 JP2015545099A JP2015545099A JP6246227B2 JP 6246227 B2 JP6246227 B2 JP 6246227B2 JP 2015545099 A JP2015545099 A JP 2015545099A JP 2015545099 A JP2015545099 A JP 2015545099A JP 6246227 B2 JP6246227 B2 JP 6246227B2
Authority
JP
Japan
Prior art keywords
compound
pyrazol
ethyl
seizures
benzothiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015545099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016501219A (ja
JP2016501219A5 (enExample
Inventor
ケヴィン リール,ジョン
ケヴィン リール,ジョン
ジェイ ポーター,ワーレン
ジェイ ポーター,ワーレン
マイケル ウィトキン,ジェフリー
マイケル ウィトキン,ジェフリー
Original Assignee
イーライ リリー アンド カンパニー
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー, イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2016501219A publication Critical patent/JP2016501219A/ja
Publication of JP2016501219A5 publication Critical patent/JP2016501219A5/ja
Application granted granted Critical
Publication of JP6246227B2 publication Critical patent/JP6246227B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2015545099A 2012-11-27 2013-11-20 Tarp−ガンマ8依存性ampa受容体アンタゴニストとしての6−((s)−1−{1−[5−(2−ヒドロキシ−エトキシ)−ピリジン−2−イル]−1h−ピラゾール−3−イル}−エチル)−3h−1,3−ベンゾチアゾール−2−オン Active JP6246227B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
US61/730,273 2012-11-27
PCT/US2013/070885 WO2014085153A1 (en) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist

Publications (3)

Publication Number Publication Date
JP2016501219A JP2016501219A (ja) 2016-01-18
JP2016501219A5 JP2016501219A5 (enExample) 2017-01-12
JP6246227B2 true JP6246227B2 (ja) 2017-12-13

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015545099A Active JP6246227B2 (ja) 2012-11-27 2013-11-20 Tarp−ガンマ8依存性ampa受容体アンタゴニストとしての6−((s)−1−{1−[5−(2−ヒドロキシ−エトキシ)−ピリジン−2−イル]−1h−ピラゾール−3−イル}−エチル)−3h−1,3−ベンゾチアゾール−2−オン

Country Status (35)

Country Link
US (1) US8765960B2 (enExample)
EP (1) EP2925754B1 (enExample)
JP (1) JP6246227B2 (enExample)
KR (1) KR101693133B1 (enExample)
CN (1) CN104797578B (enExample)
AP (1) AP2015008489A0 (enExample)
AR (1) AR093527A1 (enExample)
AU (1) AU2013352594B2 (enExample)
BR (1) BR112015011200A2 (enExample)
CA (1) CA2889243C (enExample)
CL (1) CL2015001419A1 (enExample)
CR (1) CR20150267A (enExample)
CY (1) CY1118657T1 (enExample)
DK (1) DK2925754T3 (enExample)
DO (1) DOP2015000113A (enExample)
EA (1) EA026686B1 (enExample)
ES (1) ES2618260T3 (enExample)
HR (1) HRP20170274T1 (enExample)
HU (1) HUE033447T2 (enExample)
IL (1) IL238831B (enExample)
JO (1) JO3225B1 (enExample)
MA (1) MA38126B1 (enExample)
MX (1) MX356478B (enExample)
MY (1) MY177721A (enExample)
PE (1) PE20151728A1 (enExample)
PH (1) PH12015501154B1 (enExample)
PL (1) PL2925754T3 (enExample)
PT (1) PT2925754T (enExample)
SG (1) SG11201504164VA (enExample)
SI (1) SI2925754T1 (enExample)
TN (1) TN2015000200A1 (enExample)
TW (2) TWI618705B (enExample)
UA (1) UA114345C2 (enExample)
WO (1) WO2014085153A1 (enExample)
ZA (1) ZA201503733B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
AU2016255434C1 (en) 2015-04-29 2021-09-23 Rapport Therapeutics, Inc. Azabenzimidazoles and their use as AMPA receptor modulators
BR112017023200A2 (pt) 2015-04-29 2018-08-07 Janssen Pharmaceutica Nv compostos de indolona e seu uso como moduladores do receptor de ampa
MX373652B (es) 2015-04-29 2020-04-02 Janssen Pharmaceutica Nv Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
WO2016176449A1 (en) * 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
EA036903B1 (ru) * 2016-10-26 2021-01-13 Янссен Фармацевтика Нв Соединения конденсированных бициклических пиридинов и их применение в качестве модуляторов ampa-рецептора
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ampa拮抗化合物の新規製造法
EP2177520A1 (en) * 2000-06-12 2010-04-21 Eisai R&D Management Co., Ltd. 1,5-Di(aryl or heteroaryl)-3-halo-2(1H)-pyridones as intermediates for the preparation of AMPA receptor inhibitors
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
ATE404555T1 (de) * 2004-12-17 2008-08-15 Lilly Co Eli Neue mch-rezeptorantagonisten
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
CA2739559A1 (en) * 2008-10-08 2010-04-15 Pfizer Inc. Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof
BRPI1006128A2 (pt) * 2009-01-12 2016-11-01 Cagen Inc derivados de sulfonamida
CN102985420B (zh) * 2010-06-01 2017-07-04 安吉翁生物医药有限公司 细胞色素p450抑制剂及其用途
US9527807B2 (en) * 2011-04-05 2016-12-27 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物

Also Published As

Publication number Publication date
KR20150070401A (ko) 2015-06-24
UA114345C2 (uk) 2017-05-25
PL2925754T3 (pl) 2017-07-31
MA38126B1 (fr) 2017-11-30
JO3225B1 (ar) 2018-03-08
BR112015011200A2 (pt) 2017-07-11
TW201434834A (zh) 2014-09-16
PH12015501154A1 (en) 2015-08-10
MY177721A (en) 2020-09-23
TW201825484A (zh) 2018-07-16
MX356478B (es) 2018-05-30
AP2015008489A0 (en) 2015-05-31
SG11201504164VA (en) 2015-07-30
TN2015000200A1 (en) 2016-10-03
PT2925754T (pt) 2017-02-27
EP2925754A1 (en) 2015-10-07
MA38126A1 (fr) 2017-03-31
CN104797578A (zh) 2015-07-22
CA2889243C (en) 2017-06-13
CN104797578B (zh) 2016-11-23
IL238831B (en) 2018-08-30
AU2013352594A1 (en) 2015-06-04
CA2889243A1 (en) 2014-06-05
US20140148441A1 (en) 2014-05-29
ES2618260T3 (es) 2017-06-21
CY1118657T1 (el) 2017-07-12
HUE033447T2 (en) 2017-11-28
PE20151728A1 (es) 2015-12-02
AU2013352594B2 (en) 2016-02-18
WO2014085153A1 (en) 2014-06-05
US8765960B2 (en) 2014-07-01
PH12015501154B1 (en) 2018-05-30
SI2925754T1 (sl) 2017-02-28
HRP20170274T1 (hr) 2017-04-07
MX2015006697A (es) 2015-08-05
DOP2015000113A (es) 2015-06-15
IL238831A0 (en) 2015-06-30
DK2925754T3 (en) 2017-02-20
JP2016501219A (ja) 2016-01-18
WO2014085153A8 (en) 2014-07-31
CL2015001419A1 (es) 2015-10-02
EA026686B1 (ru) 2017-05-31
AR093527A1 (es) 2015-06-10
KR101693133B1 (ko) 2017-01-04
TWI618705B (zh) 2018-03-21
HK1209116A1 (en) 2016-03-24
EA201590823A1 (ru) 2015-08-31
CR20150267A (es) 2015-09-16
ZA201503733B (en) 2017-09-27
EP2925754B1 (en) 2016-12-28

Similar Documents

Publication Publication Date Title
JP6246227B2 (ja) Tarp−ガンマ8依存性ampa受容体アンタゴニストとしての6−((s)−1−{1−[5−(2−ヒドロキシ−エトキシ)−ピリジン−2−イル]−1h−ピラゾール−3−イル}−エチル)−3h−1,3−ベンゾチアゾール−2−オン
CN106103415B (zh) 吲唑和其用途
WO2019243533A1 (en) Oga inhibitor compounds
ES2443578T3 (es) Compuestos de tetrahidrotriazolopiridina como potenciadores de receptores selectivos de mGlu5 útiles para el tratamiento de la esquizofrenia
EA026655B1 (ru) 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
JP2021536496A (ja) フェノキシ−ピリジル−ピリミジン化合物及び使用方法
JP6186440B2 (ja) キナーゼ阻害剤としてのジヒドロピロリジノピリミジン
EP3204374B1 (en) Isoindoline derivatives
AU2023329097A1 (en) Deuterated pyrimidin-2-yl sulfonamide derivatives
WO2019241644A1 (en) Novel small molecule anticancer agents, combinations and uses thereof
CN112004811B (zh) 调节ampa受体功能的化合物
WO2019163865A1 (ja) 含窒素複素環を有するジベンゾアゼピン誘導体
TW202333671A (zh) 氘化有機化合物及其用途
HK1209116B (en) 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}-ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist
JP5755821B2 (ja) Mglu2/3アゴニスト
JP2025532560A (ja) 神経変性障害及び癌の治療における化合物及びその使用
Katzman Navigating the Roads to Drug Discovery Part 1: Design, Synthesis, and Biological Evaluation of a Novel Class of Allosteric Modulators of N-Methyl-D-Aspartate Receptor Function Part 2: Discovery of Novel Tetrahydroisoquinoline (THIQ)-Based CXCR4 Antagonists and Conformational Analysis of Structurally Similar CXCR4 Antagonists
TW201130856A (en) Bicyclic thiazoles as allosteric modulators of mGluP5 receptors
TW201309691A (zh) 促代謝性麩胺酸受體調節劑

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171017

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171019

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171114

R150 Certificate of patent or registration of utility model

Ref document number: 6246227

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250